{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:06:13Z","timestamp":1761930373952,"version":"3.37.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13668-1","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T13:26:41Z","timestamp":1739626001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urine proteomics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Chenyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runchun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"13668_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"13668_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/cac2.12197","volume":"41","author":"H Qiu","year":"2021","unstructured":"Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun Lond Engl. 2021;41:1037\u201348.","journal-title":"Cancer Commun Lond Engl"},{"key":"13668_CR3","doi-asserted-by":"publisher","first-page":"692941","DOI":"10.3389\/fmolb.2021.692941","volume":"8","author":"H Zheng","year":"2021","unstructured":"Zheng H, Chen C. Downregulation of CacyBP by CRISPR\/dCas9-KRAB Prevents Bladder Cancer Progression. Front Mol Biosci. 2021;8:692941.","journal-title":"Front Mol Biosci."},{"key":"13668_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/jjco\/hyz017","volume":"49","author":"S Kandori","year":"2019","unstructured":"Kandori S, Kojima T, Nishiyama H. The updated points of TNM classification of urological cancers in the 8th edition of AJCC and UICC. Jpn J Clin Oncol. 2019;49:421\u20135.","journal-title":"Jpn J Clin Oncol."},{"key":"13668_CR5","first-page":"730","volume":"24","author":"J Miyazaki","year":"2017","unstructured":"Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol Off J Jpn Urol Assoc. 2017;24:730\u20134.","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"13668_CR6","first-page":"507","volume":"96","author":"KC DeGeorge","year":"2017","unstructured":"DeGeorge KC, Holt HR, Hodges SC. Bladder Cancer: Diagnosis and Treatment. Am Fam Physician. 2017;96:507\u201314.","journal-title":"Am Fam Physician"},{"key":"13668_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404\u201323.","journal-title":"CA Cancer J Clin"},{"key":"13668_CR8","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1038\/onc.2015.326","volume":"35","author":"E Sanchez-Lopez","year":"2016","unstructured":"Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A, et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene. 2016;35:2634\u201344.","journal-title":"Oncogene"},{"key":"13668_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.cmet.2019.07.015","volume":"30","author":"P Bieniasz-Krzywiec","year":"2019","unstructured":"Bieniasz-Krzywiec P, Mart\u00edn-P\u00e9rez R, Ehling M, Garc\u00eda-Caballero M, Pinioti S, Pretto S, et al. Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer. Cell Metab. 2019;30:917-936.e10.","journal-title":"Cell Metab"},{"key":"13668_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/imt-2016-0135","volume":"9","author":"AJ Petty","year":"2017","unstructured":"Petty AJ, Yang Y. Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy. 2017;9:289\u2013302.","journal-title":"Immunotherapy"},{"key":"13668_CR11","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/cancers6031670","volume":"6","author":"T Chanmee","year":"2014","unstructured":"Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6:1670\u201390.","journal-title":"Cancers"},{"key":"13668_CR12","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1002\/jcb.27646","volume":"120","author":"M Najafi","year":"2019","unstructured":"Najafi M, Hashemi Goradel N, Farhood B, Salehi E, Nashtaei MS, Khanlarkhani N, et al. Macrophage polarity in cancer: A review. J Cell Biochem. 2019;120:2756\u201365.","journal-title":"J Cell Biochem"},{"key":"13668_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13046-023-02768-0","volume":"42","author":"J Ma","year":"2023","unstructured":"Ma J, Ma R, Zeng X, Zhang L, Liu J, Zhang W, et al. Lysosome blockade induces divergent metabolic programs in macrophages and tumours for cancer immunotherapy. J Exp Clin Cancer Res CR. 2023;42:192.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"13668_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13045-022-01366-5","volume":"15","author":"K Beider","year":"2022","unstructured":"Beider K, Voevoda-Dimenshtein V, Zoabi A, Rosenberg E, Magen H, Ostrovsky O, et al. CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression. J Hematol Oncol. 2022;15:144.","journal-title":"J Hematol Oncol"},{"key":"13668_CR15","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/s41467-022-29164-0","volume":"13","author":"G Song","year":"2022","unstructured":"Song G, Shi Y, Meng L, Ma J, Huang S, Zhang J, et al. Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma. Nat Commun. 2022;13:1642.","journal-title":"Nat Commun"},{"key":"13668_CR16","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.chembiol.2005.07.009","volume":"12","author":"FV Rao","year":"2005","unstructured":"Rao FV, Andersen OA, Vora KA, Demartino JA, van Aalten DMF. Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes. Chem Biol. 2005;12:973\u201380.","journal-title":"Chem Biol"},{"key":"13668_CR17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/jmedgenet-2013-101908","volume":"50","author":"AD Kjaergaard","year":"2013","unstructured":"Kjaergaard AD, Johansen JS, Nordestgaard BG, Bojesen SE. Genetic variants in CHI3L1 influencing YKL-40 levels: resequencing 900 individuals and genotyping 9000 individuals from the general population. J Med Genet. 2013;50:831\u20137.","journal-title":"J Med Genet"},{"key":"13668_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-020-00303-7","volume":"5","author":"T Zhao","year":"2020","unstructured":"Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5:201.","journal-title":"Signal Transduct Target Ther"},{"key":"13668_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1471-2148-7-96","volume":"7","author":"JD Funkhouser","year":"2007","unstructured":"Funkhouser JD, Aronson NN. Chitinase family GH18: evolutionary insights from the genomic history of a diverse protein family. BMC Evol Biol. 2007;7:96.","journal-title":"BMC Evol Biol"},{"key":"13668_CR20","doi-asserted-by":"publisher","first-page":"35282","DOI":"10.1038\/srep35282","volume":"6","author":"E Kumagai","year":"2016","unstructured":"Kumagai E, Mano Y, Yoshio S, Shoji H, Sugiyama M, Korenaga M, et al. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6:35282.","journal-title":"Sci Rep"},{"key":"13668_CR21","doi-asserted-by":"publisher","first-page":"1056397","DOI":"10.3389\/fimmu.2022.1056397","volume":"13","author":"B Ma","year":"2022","unstructured":"Ma B, Kamle S, Akosman B, Khan H, Lee C-M, Lee CG, et al. CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4\/B7 axis. Front Immunol. 2022;13:1056397.","journal-title":"Front Immunol"},{"key":"13668_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3892\/or.2014.3195","volume":"32","author":"Y Akiyama","year":"2014","unstructured":"Akiyama Y, Ashizawa T, Komiyama M, Miyata H, Oshita C, Omiya M, et al. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. Oncol Rep. 2014;32:159\u201366.","journal-title":"Oncol Rep"},{"key":"13668_CR23","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1007\/s12035-016-9878-2","volume":"54","author":"G Qin","year":"2017","unstructured":"Qin G, Li X, Chen Z, Liao G, Su Y, Chen Y, et al. Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis. Mol Neurobiol. 2017;54:3264\u201370.","journal-title":"Mol Neurobiol"},{"key":"13668_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/ijc.26379","volume":"131","author":"S Libreros","year":"2012","unstructured":"Libreros S, Garcia-Areas R, Shibata Y, Carrio R, Torroella-Kouri M, Iragavarapu-Charyulu V. Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model. Int J Cancer. 2012;131:377\u201386.","journal-title":"Int J Cancer"},{"key":"13668_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10585-020-10032-4","volume":"37","author":"KI Ansari","year":"2020","unstructured":"Ansari KI, Bhan A, Liu X, Chen MY, Jandial R. Astrocytic IGFBP2 and CHI3L1 in cerebrospinal fluid drive cortical metastasis of HER2+breast cancer. Clin Exp Metastasis. 2020;37:401\u201312.","journal-title":"Clin Exp Metastasis"},{"key":"13668_CR26","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/1878-0261.13152","volume":"16","author":"JE Yu","year":"2022","unstructured":"Yu JE, Yeo IJ, Son DJ, Yun J, Han S-B, Hong JT. Anti-Chi3L1 antibody suppresses lung tumor growth and metastasis through inhibition of M2 polarization. Mol Oncol. 2022;16:2214\u201334.","journal-title":"Mol Oncol"},{"key":"13668_CR27","doi-asserted-by":"publisher","first-page":"e1505","DOI":"10.1002\/cti2.1505","volume":"13","author":"B Wang","year":"2024","unstructured":"Wang B, Chen K, Gao M, Sun X, He W, Chen J, et al. Chitinase 3-like 1 expression associated with lymphatic metastasis and prognosis in urothelial carcinoma of the bladder. Clin Transl Immunology. 2024;13:e1505.","journal-title":"Clin Transl Immunology"},{"key":"13668_CR28","doi-asserted-by":"publisher","first-page":"257.e19","DOI":"10.1016\/j.urolonc.2016.02.003","volume":"34","author":"O Yasar","year":"2016","unstructured":"Yasar O, Akcay T, Obek C, Turegun FA. Diagnostic potential of YKL-40 in bladder cancer. Urol Oncol. 2016;34:257.e19-257.e24.","journal-title":"Urol Oncol"},{"key":"13668_CR29","doi-asserted-by":"publisher","first-page":"299.e7","DOI":"10.1016\/j.urolonc.2019.01.001","volume":"37","author":"Y-E Lee","year":"2019","unstructured":"Lee Y-E, Chan T-C, Tian Y-F, Liang P-I, Shiue Y-L, Chen Y-S, et al. High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder. Urol Oncol. 2019;37:299.e7-299.e18.","journal-title":"Urol Oncol"},{"key":"13668_CR30","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.urolonc.2014.02.004","volume":"32","author":"S Tschirdewahn","year":"2014","unstructured":"Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendr\u00f6i A, Schmid KW, et al. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol Oncol. 2014;32:663\u20139.","journal-title":"Urol Oncol"},{"key":"13668_CR31","doi-asserted-by":"publisher","first-page":"15990","DOI":"10.3390\/ijms242115990","volume":"24","author":"L-Y Xiao","year":"2023","unstructured":"Xiao L-Y, Su Y-L, Huang S-Y, Chen Y-H, Hsueh P-R. Chitinase 3-like-1 Expression in the Microenvironment Is Associated with Neutrophil Infiltration in Bladder Cancer. IJMS. 2023;24:15990.","journal-title":"IJMS"},{"key":"13668_CR32","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1186\/bcr3195","volume":"14","author":"HJ Cho","year":"2012","unstructured":"Cho HJ, Jung JI, Lim DY, Kwon GT, Her S, Park JH, et al. Bone marrow-derived, alternatively activated macrophages enhance solid tumor growth and lung metastasis of mammary carcinoma cells in a Balb\/C mouse orthotopic model. Breast Cancer Res BCR. 2012;14:R81.","journal-title":"Breast Cancer Res BCR"},{"key":"13668_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jb\/mvr136","volume":"151","author":"M Kawata","year":"2012","unstructured":"Kawata M, Koinuma D, Ogami T, Umezawa K, Iwata C, Watabe T, et al. TGF-\u03b2-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. J Biochem (Tokyo). 2012;151:205\u201316.","journal-title":"J Biochem (Tokyo)."},{"key":"13668_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ccr.2011.02.006","volume":"19","author":"J Chen","year":"2011","unstructured":"Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011;19:541\u201355.","journal-title":"Cancer Cell"},{"key":"13668_CR35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood-2009-12-257832","volume":"116","author":"A Fantin","year":"2010","unstructured":"Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhozhij S, et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood. 2010;116:829\u201340.","journal-title":"Blood"},{"key":"13668_CR36","doi-asserted-by":"publisher","first-page":"115838","DOI":"10.1016\/j.bcp.2023.115838","volume":"217","author":"M Li","year":"2023","unstructured":"Li M, Che N, Liu X, Xuan Y, Jin Y. Dauricine regulates prostate cancer progression by inhibiting PI3K\/AKT-dependent M2 polarization of macrophages. Biochem Pharmacol. 2023;217:115838.","journal-title":"Biochem Pharmacol"},{"key":"13668_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-017-0408-0","volume":"10","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zhang S, Wang Q, Zhang X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. 2017;10:36.","journal-title":"J Hematol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13668-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13668-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13668-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T13:26:43Z","timestamp":1739626003000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13668-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13668"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13668-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experiments on patients' urine specimens were authorized by the Ethics Committee of the Second Hospital of Lanzhou University. Informed consent was obtained from all participants before publication of this study. All animals were kept in a pathogen-free environment. The procedures for the care and use of the animals were approved by the Ethics Committee of the Second Hospital of Lanzhou University, and all applicable institutional and governmental regulations regarding the ethical use of animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"271"}}